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Abstract
Background: MicroRNAs (miRs) are small non-coding RNAs that play an important role in cancer development where they
can act as oncogenes or as tumor-suppressors. miR-34a is a tumor-suppressor that is frequently downregulated in a number
of tumor types. However, little is known about the role of miR-34a in head and neck squamous cell carcinoma (HNSCC).
Methods and Results: miR-34a expression in tumor samples, HNSCC cell lines and endothelial cells was examined by real
time PCR. Lipofectamine-2000 was used to transfect miR-34a in HNSCC cell lines and human endothelial cells. Cell-
proliferation, migration and clonogenic survival was examined by MTT, Xcelligence system, scratch assay and colony
formation assay. miR-34a effect on tumor growth and tumor angiogenesis was examined by in vivo SCID mouse xenograft
model. Our results demonstrate that miR-34a is significantly downregulated in HNSCC tumors and cell lines. Ectopic
expression of miR-34a in HNSCC cell lines significantly inhibited tumor cell proliferation, colony formation and migration.
miR-34a overexpression also markedly downregulated E2F3 and survivin levels. Rescue experiments using microRNA
resistant E2F3 isoforms suggest that miR-34a-mediated inhibition of cell proliferation and colony formation is
predominantly mediated by E2F3a isoform. In addition, tumor samples from HNSCC patients showed an inverse
relationship between miR-34a and survivin as well as miR-34a and E2F3 levels. Overexpression of E2F3a completely rescued
survivin expression in miR-34a expressing cells, thereby suggesting that miR-34a may be regulating survivin expression via
E2F3a. Ectopic expression of miR-34a also significantly inhibited tumor growth and tumor angiogenesis in a SCID mouse
xenograft model. Interestingly, miR-34a inhibited tumor angiogenesis by blocking VEGF production by tumor cells as well as
directly inhibiting endothelial cell functions.
Conclusions: Taken together, these findings suggest that dysregulation of miR-34a expression is common in HNSCC and
modulation of miR34a activity might represent a novel therapeutic strategy for the treatment of HNSCC.
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Introduction
Head and neck squamous cell carcinoma (HNSCC), which
includes cancers of oral cavity, oropharynx, larynx, and hypo-
pharynx accounts for approximately 600,000 new cases every year
and is sixth leading cancer by incidence worldwide [1]. The most
important risk factors identified so far are tobacco use and alcohol
consumption, which seem to have a synergistic effect [2]. In recent
years, the incidence of oropharyngeal cancers, particularly in the
western world, has markedly increased, which may be related to
increase in oral and oropharyngeal human papillomavirus (HPV)
infections [3]. Despite advancements in surgical and other
therapeutic regimens, 5 year survival rates for head and neck
patients have stayed around 50% during the last two decades [4].
Patients that survive with surgery and/or chemo-radiation
treatment (CRT) often live with significant cosmetic and functional
defects. The limited information available on the molecular
carcinogenesis of HNSCC and the genetic and biological
heterogeneity of the disease has hampered the development of
novel therapeutic strategies.
Cancer is a complex genetic disease in which deregulated cell
growth arises due to defects in major pathways that are
fundamental for normal homeostasis [1]. Evidence is emerging
that alterations in the expression of microRNAs (miRs) may
play a key role in cancer development and progression [5].
MicroRNAs (miRs), first described about 18 years ago in
Caenorhabditis elegans [6], are small non-coding RNAs that act in
concert to regulate expression of myriad target Proteins. Today
more than 17000 microRNA’s in over 153 species have been
identified (miRBase Sequence Database - Release 17; www.
miRbase.org), of which around 1400 are in humans. Most miRs
are evolutionarily conserved and often found in clusters [7]. In
mammals, mature miRs are recognized by specific proteins to
form RNA-inducing silencing complex (RISC) and associate
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messenger RNA (mRNA) to suppress translation or occasionally
induce their degradation [5]. Changes in miR expression profile
have been shown to be associated with a variety of human
cancers [8,9,10,11]. More importantly, it has been found that
they are differentially expressed in tumor tissues compared to
noncancerous tissues [12,13,14,15,16]. miRs can function as
tumor suppressors or oncogenes, depending on whether they
specifically target oncogenes or tumor suppressor genes.
Therefore, understanding the molecular mechanisms by which
these miRs play a role in deregulated cellular signaling in the
head and neck cancer cell might help develop better therapeutic
strategies for treatment of this disease.
Recent studies have highlighted the role of miR-34a as
a tumor suppressor in a number of tumor types including
prostate cancer, hepatocellular carcinoma, neuroblastoma and
colon cancer [17,18,19,20,21,22]. miR-34a was originally
discovered as a potential tumor suppressor that is down-
regulated and induces apoptosis in neuroblastoma cells [20].
Subsequently, it was shown to be a transcriptional target of p53
protein [23,24]. Functionally miR-34a was found to affect
tumor cell proliferation, apoptosis, senescence, invasion, metas-
tasis and drug resistance [21,22,23,25,26,27]. However, very
little is known about the role and expression status of miR-34a
in head and neck cancers. In this study, we examined if loss of
miR-34a in head and neck cancers promotes tumor growth and
tumor angiogenesis. Our results demonstrate that miR-34a
expression is significantly downregulated in primary tumors
from head and neck cancer patients as well as in head and neck
cancer cell lines. Ectopic expression of miR-34a in head and
neck cell lines significantly inhibited tumor cell proliferation,
migration and colony formation by downregulating the expres-
sion of E2F3 and survivin. In addition, miR-34a significantly
inhibited tumor growth and tumor angiogenesis in a SCID
mouse xenograft model. Interestingly, miR-34a inhibited tumor
angiogenesis by blocking VEGF secretion by tumor cells as well
as directly inhibiting endothelial cell functions.
Results
miR-34a Expression is Significantly Downregulated in
Primary Tumor Samples and Tumor Cell Lines from the
Head and Neck Cancer Patients
We measured miR-34a expression levels in 30 frozen samples
from head and neck cancer patients (15 tumors and 15 adjacent
normal controls) by TaqMan real time RT-PCR. Out of 15 tumor
samples, 6 were from oral cavity, 5 from oropharynx and 4 from
larynx. Our results show that miR-34a expression is significantly
decreased (Mann-Whitney test; p value 0.0226) in head and neck
tumors as compared to adjacent normal tissue (Figure 1A). We did
not observe any significant differences in miR-34a levels in tumor
samples from the different head and neck sub-sites. We next
examined if head and neck tumor cell lines also exhibit similar
downregulated expression of miR-34a as compared to normal
keratinocyes. We examined miR-34a levels in 3 different normal
keratinocyte cell types [human oral keratinocytes (HOK); human
epidermal keratinocytes, adult (HEKa) and human epidermal
keratinocytes, neonatal (HEKn)] and 9 head and neck cancer cell
lines. Indeed, miR-34a expression was markedly downregulated in
all the head and neck cancer cell lines that were examined
(Figure 1B).
miR-34a Inhibits Head and Neck Tumor Cell Proliferation,
Colony Formation and Migration
Next, we examined the role of miR-34a on head and neck
tumor cell proliferation, colony formation and migration. 50 nM
of pre-miR-34a or scrambled control RNA was used to transfect
head and neck cancer cell lines. Ectopic expression of miR-34a in
transfected cells (UM-SCC-74A) was confirmed by RT-PCR
(Figure 2A). Similar ectopic expression of miR-34a was observed
in UM-SCC-74B cells (data not shown). We performed parallel
experiments for cell proliferation using Xcelligence system and
MTT assay (Roche Diagnostics, Indianapolis, IN). Ectopic
expression of miR-34a significantly inhibited cell proliferation in
UM-SCC-74A cells (MTT assay; Figure 2B & Figure S2 and
Xcelligence assay; Figure 2C) and UM-SCC-74B cells (Figure 2D).
Similarly, miR-34a transfection in both the head and neck cancer
cell lines markedly decreased tumor cell colony formation
(Figure 2E-H) and tumor cell migration (Scratch assay; Figure 3A
and Xcelligence migration assay; Figure 3B-C). Cell migration by
Figure 1. Expression of miR-34a is downregulated in HNSCC
cell lines and patient’s tumor samples. A: miR-34a expression was
examined in primary tumor samples (n=15) or in adjacent normal
mucosa (n=15) of head and neck cancer patients by quantitative real
time PCR (RT-PCR) and statistical significance was analyzed by Mann-
Whitney test (p value 0.022). B: miR-34a expression was analyzed in 9
head and neck cancer cell lines by RT-PCR and compared with 3 normal
human keratinocyes [human oral keratinocytes (HOK); human epider-
mal keratinocytes, adult (HEKa) and human epidermal keratinocytes,
neonatal (HEKn)].
doi:10.1371/journal.pone.0037601.g001
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cell migration inhibition in UMSCC-74A and UM-SCC-74B cells,
respectively (Figure 3B-C). Whereas only 20% cell proliferation
inhibition (Figure 2) was observed at the same time point (24 hrs),
thereby suggesting that miR-34a predominantly affected cell
migration at 24 hrs.
miR-34a Inhibits Tumor Cell Proliferation and Colony
Formation by Downregulating E2F3 and Survivin
We next sought to identify the target mRNAs of miR-34a that
regulate head and neck tumor cell function. TargetScan data base
(www.targetscan.org) search revealed several growth regulatory
mRNAs that contains conserved miR-34a recognition sites in their
39-UTR. In this study, we focused our attention to E2F3a and
E2F3b because E2F3 family of transcription factors play an
important role in cell cycle regulation, cell proliferation and
differentiation [28,29,30]. To confirm that miR-34a regulates the
endogenous expression of E2F3a and E2F3b, we ectopically
introduced miR-34a in UM-SCC-74A cells and examined E2F3a/
b levels in these cells 72 hrs post transfection. We used two
different antibodies against E2F3, including a monoclonal anti-
body that specifically recognizes the unique N-terminal portion of
E2F3a (Figure 4A-B, top panel) and this antibody is referred as
E2F3a. We also used a polyclonal antibody that recognizes a region
close to C terminus, which is common to both E2F3a and E2F3b
[29] (Figure 4A-B, middle panel). Expression of both E2F3a and
E2F3b proteins was markedly downregulated in miR-34a
transfected cells as compared to cells transfected with scrambled
control RNA (Figure 4A).
As both E2F3 isoforms were downregulated in miR-34a
transfected cells, we performed isoform-specific rescue experi-
ments to understand the specific contribution of E2F3a and E2F3b
in miR-34a mediated tumor suppressor function. We used
microRNA resistant constructs for E2F3a and E2F3b [29]. These
constructs were generated by modifying the microRNA targeting
sequence by introducing three silent base changes (a gift from Dr.
David Dynlacht, New York University). Expression of E2F3a and
E2F3b in UM-SCC-74A cells showed significantly elevated
protein levels as compared to cells transfected with control vector
(VC) (Figure 4B). Overexpression of E2F3a or E2F3b in UM-
SCC-74A cells showed a modest increase in cell proliferation (12%
and 6% respectively; Figure 4C). Interestingly, E2F3a over-
expression in UM-SCC-74A cells significantly rescued tumor cells
from miR-34a-mediated inhibition of cell proliferation (56%,
Figure 4C) and colony formation (86%, Figure 4D), whereas
E2F3b was only partially effective in reversing miR-34a-mediated
inhibition of cell proliferation (19%, Figure 4C) and colony
formation (26%, Figure 4D).
Survivin, encoded by the gene BIRC5 is a member of the
inhibitor of apoptosis proteins (IAP) family of molecules [31].
Survivin is aberrantly expressed in many malignancies including
HNSCC [32] and has been shown to play a role in cancer
progression and resistance to therapy [33]. Recently, miR-34a was
shown to decrease survivin promoter activity [34]. In addition,
survivin promoter activity is also regulated by E2F3, a key miR-
34a target protein [35]. Since ectopic expression of miR34a
inhibits E2F3 expression, we further examined if survivin
expression is regulated by miR-34a via E2F3. Indeed, miR-34a
transfection in UM-SCC-74A cells significant decreased survivin
protein levels (Figure 4E). We next examined if overexpression of
miR resistant E2F3a or E2F3b could rescue survivin expression in
miR-34a treated cells. Overexpression of E2F3a was able to
completely rescue survivin expression in miR-34a transfected UM-
SCC-74A cells, whereas E2F3b was only partially effective
(Figure 4E). To further validate the cell line findings of inverse
relationship between miR-34a and its target proteins survivin and
E2F3, we examined miR-34a, survivin and E2F3 mRNA levels in
the primary head and neck tumor samples. All 15 tumor samples
showed an inverse relationship between miR-34a levels and
survivin (Pearson r value 0.89; p value 0.0001). 14/15 patient
samples showed low levels of miR-34a and high levels of survivin
mRNA. One sample (Patient # 10) showed high miR-34a and low
survivin levels (Figure 4F). Similarly, miR-34a levels were inversely
correlated with E2F3 levels (Pearson r value 0.81; p value 0.0002).
miR-34a Inhibits Tumor Growth, in vivo
To confirm the anti-tumor effects on miR-34a in vivo,w e
implanted two head and neck cell lines either expressing miR-34a
or scrambled control in the right or left flanks of SCID mice,
respectively. Representative photographs of SCID mice bearing
tumors at day 18 and dissected tumors are shown in Figure 5C-F.
Ectopic expression of miR-34a expression in both the tumor cell
lines significantly inhibited tumor growth in SCID mice (Figure 5).
In order to confirm that ectopic expression of miR-34a stayed
throughout the in vivo experiments, we isolated RNA from UM-
SCC-74A tumor samples at the end of study and performed real
time RT-PCR. Indeed, ectopic expression of miR-34a was
maintained in the tumor cells throughout the study (Figure 5G).
miR-34a Inhibits Tumor Angiogenesis by
Downregulating VEGF Secretion from Tumor Cells
In our in vivo tumor growth study, in addition to smaller tumor
size, we also observed that tumors were visually less vascular in
miR-34a transduced group. VEGF is a key angiogenic protein and
recent studies have shown that a number of miR-34a target
proteins including E2F3, Myc and c-met can regulate VEGF
expression [36,37,38]. Therefore, we next examined if ectopic
expression of miR-34a affected tumor angiogenesis. UM-SCC-
74A tumors expressing miR-34a showed a significant decrease in
blood vessel density (83%) as compared to tumors expressing
scrambled control RNA (Figure 6A-B). Similarly, UM-SCC-74B
tumors showed 87% decrease in tumor blood vessel density
(Figure 6D-E). We next examined if miR-34a inhibits tumor
angiogenesis by blocking VEGF production by the tumor cells.
miR-34a was ectopically expressed in tumor cells and VEGF
(VEGF A) levels in the culture supernatants was quantified by
ELISA. Untreated UM-SCC-74A cells produced very high levels
of VEGF (1247 pg/ml/10
6cells) and miR-34a transduction
significantly reduced VEGF production (56%) (Figure 6C). Sim-
ilarly, miR-34a transfection in UM-SCC-74B cells significantly
reduced VEGF production (45%) (Figure 6F).
miR-34a Inhibits Endothelial Cell Proliferation, Migration
and Tube Formation
In our previous study, we have shown Bcl-2 expression is
significantly elevated in tumor-associated endothelial cells (EC-
Bcl-2) [39,40] and our results from this study suggest that miR-34a
expression is significantly decreased in Bcl-2 expressing endothelial
cells as compared to endothelial cells containing empty vector
alone (EC-VC) (Figure 7A). We next examined if miR-34a could
directly affect angiogenic function of endothelial cells in vitro.
Transfection of miR-34a in endothelial cells significantly inhibited
cell proliferation (85%) and migration (84%) (Figure 7B-C).
Similarly, miR-34a significantly inhibited the ability of endothelial
cells to form tubular structure on Matrigel (Figure 7Da-b). In
addition, ectopic expression of miR-34a in endothelial cells
miR-34a Inhibits HNSCC Tumor Growth
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37601Figure 2. Ectopic expression of miR-34a inhibits tumor cell proliferation and colony formation. A: Tumor cells (UM-SCC-74A) were
transfected with miR-34a or scrambled control microRNAs (SC) and miR-34a expression was analyzed by quantitative real time PCR (RT-PCR). *,
represent a significant difference (p,0.05). B: Cell proliferation was measured by MTT assay at different time points. Percentage cell proliferation for
tumor cells transfected with miR-34a was calculated by adjusting proliferation index of tumor cells transfected with SC to 100. *, represent
a significant inhibition (p,0.05) of cell proliferation in miR-34a expressing tumor cells as compared to SC. C-D: Cell proliferation was measured using
Xcelligence system using the RTCA DP instrument. Percentage cell proliferation for tumor cells transfected with ectopic miR-34a was calculated by
adjusting proliferation index of tumor cells transfected with SC to 100. *, represent a significant inhibition (p,0.05) of cell proliferation in miR-34a
expressing tumor cells at 48 hrs as compared to SC. E-H: Effect of miR-34a on tumor cell colony formation (E-F; UM-SCC-74A and G-H; UM-SCC-74B)
was examined by culturing tumor cells (5,000) in 60 mm Petri dishes for 14 days. Colony numbers in each assay was quantified by Alpha Innotech
(San Leandro, CA) imaging software and percentage colony formation for tumor cells transfected with miR-34a was calculated by adjusting tumor
cells transfected with SC to 100. *, represent a significant inhibition (p,0.05) of tumor cell colony formation in miR-34a expressing tumor cells as
compared to SC.
doi:10.1371/journal.pone.0037601.g002
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b, SIRT1, survivin and CDK4 (Figure 7E).
Discussion
Head and neck squamous cell carcinomas (HNSCC) are the
most frequent malignancies of the upper aerodigestive tract [41].
In many cases, these cancers are diagnosed at a very late stage (III
or IV). These cancers are known to be very severe and they can
strip away a person’s voice, distort the face and rob the basic
abilities to eat, drink and swallow. Although advancements in the
techniques for surgery, radiation and chemotherapy have in-
creased the local control of HNSCC, the overall survival rates
have not improved significantly over the last three decades
[42,43]. The high mortality rate in these patients is in large
measure due to local tissue invasion by the primary tumor as well
as acquisition of resistance to chemotherapy and radiation
Figure 3. miR-34a significantly inhibits tumor cell migration. A: Tumor cell (UM-SCC-74A) motility was examined by scratch assay. Red dotted
lines mark the edges at the start of experiments, and green dotted lines mark the edges at the end of experiments. B-C: Tumor cell migration was
analyzed by Xcelligence system. Percentage cell migration for cells ectopically expressing miR-34 was calculated by adjusting migration index for
tumor cells transduced with SC to 100%. *, represent a significant inhibition (p,0.05) of cell migration in miR-34a expressing tumor cells as compared
to SC.
doi:10.1371/journal.pone.0037601.g003
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strategies are developed to increase the long-term survival of
these patients as well as decrease the adverse effects associated with
concurrent chemo-radiation regimen. In order to develop tumor
specific therapies, recent research efforts have attempted to exploit
the biological differences that may exist between normal and
malignant cells.
Recent studies have demonstrated that microRNAs are
differentially expressed in tumors as compared to normal tissues
[8]. In our real-time PCR analysis of the head and neck cell lines,
miR-34a expression was markedly downregulated in all the
HNSCC cell lines that we tested. Similarly, Scapoli et al, have
shown in their recent study that miR-34a levels are significantly
downregulated in head and neck squamous cell carcinoma [44]. It
is now being recognized that head and neck cancers can be
subdivided into two distinct tumor types; HPV-negative and HPV-
positive tumors and these tumor types have significantly different
clinical outcome [45,46]. Recently, HPV infection was shown to
down-regulate miR-34a levels by destabilizing tumor suppressor
p53 protein in cervical cancer [47,48]. However, in our study, we
did not observe any significant difference in miR-34a levels in
HPV-positive as compared to HPV-negative head and neck
cancer cell lines. In another study, Wald et al, also did not observe
any significant difference in miR-34a levels in HPV-positive verses
HPV-negative head and neck cancer cell lines [49]. This could be
due to the fact that very few HPV positive head and neck cancer
cell lines are available due to the difficulty in establishing HPV
positive head and neck cell lines. In addition, the few HPV positive
cell lines that are available might not represent the true nature of
HPV positive head and neck tumors. We therefore selected two
HNSCC cell lines (UM-SCC-74A and UM-SCC-74B) that are
HPV negative and contain functional wild-type p53 for the in vitro
and in vivo experiments, although they were not among the cell
lines with the lowest miR-34a expression. The comparatively
Figure 4. miR-34a mediates its biological function by downregulating E2F3 and survivin levels. A: UM-SCC-74A cells were transfected
with miR-34a or scrambled control (SC). Seventy two hrs after transfection whole cell lysate was prepared and Western blotted using antibody
specific for E2F3a (top panel) or antibody that binds both E2F3a and E2F3b (middle panel). Equal protein loading in Western blotting was verified by
stripping the blots and reprobing with tubulin antibody. B: MicroRNA resistant E2F3a or E2F3b were stably overexpressed in UM-SCC-74A cells by
retroviral vector and E2F3a and E2F3b overexpression was verified by Western blot analysis. C: UM-SCC-74A cells overexpressing E2F3a, E2F3b or
vector alone (VC) were ectopically transfected with miR-34a or scrambled control (SC). After 72 hrs, cell proliferation was measured using Xcelligence
system. D: Tumor cell colony formation was examined by culturing tumor cells (5,000) in 60 mm Petri dishes for 14 days and colony numbers is each
assay was quantified by Alpha Innotech (San Leandro, CA) imaging software. E: UM-SCC-74A cells overexpressing E2F3a, E2F3b or vector alone (VC)
were ectopically transfected with miR-34a or SC. After 72 hrs, whole cell lysates were Western blotted for survivin. Equal protein loading in Western
blotting was verified by stripping the blots and reprobing with tubulin antibody. F: miR-34a, survivin and E2F3 mRNA expression from primary tumors
of 15 head and neck cancer patients was analyzed by real time RT-PCR.
doi:10.1371/journal.pone.0037601.g004
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37601Figure 5. miR-34a inhibits tumor growth in vivo. Tumor cells transfected with miR-34a or SC were mixed with 100 ml of Matrigel and injected
subcutaneously in the left and right flanks of SCID mice respectively (n=5). Tumor volume measurements began on day 3 and continued twice
a week until the end of the study. The length and width of the tumors were measured using a digital caliper and tumor volumes were calculated
using the formula, volume (mm
3)=L 6W
2/2 (length L, mm; width W, mm). After 18 days, tumors samples were carefully removed. A-B: Tumor growth
curves for UM-SCC-74A and UM-SCC-74B respectively. *, represent a significant inhibition (p,0.05) of tumor growth in miR-34a group cells as
compared to SC. C-D: Representative photographs of mice bearing UM-SCC-74A or UM-SCC-74B tumors. Green and red circles are used to highlights
tumor cells transfected with scrambled control (SC) or miR-34a, respectively. E-F: Representative photographs for UM-SCC-74A and UM-SCC-74B
tumors at day 18, respectively. G: miR-34a levels in UM-SCC-74A tumors at the end of the in vivo experiments. *, represent a significant difference
(p,0.05).
doi:10.1371/journal.pone.0037601.g005
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the presence of wild-type p53 in these cells as miR-34a has been
shown to be a direct transcriptional target of p53 [23,24]. UM-
SCC-74B cell line is derived from an intraoral head and neck
tumor and it is a relatively sensitive cell line to chemotherapy and
radiation treatment. In contrast, UM-SCC-74A cell line is derived
from the base of the tongue tumor and is highly resistant to both
chemotherapy and radiation treatment [50].
Similar to HNSCC cell lines, miR-34a expression was also
significantly downregulated in tumor samples from head and neck
cancer patients. This remarkable decrease in miR-34a in head and
neck tumors suggested to us that its deregulation in HNSCC may
be playing a role in the progression of head and neck cancer. To
test this hypothesis, we performed a series of experiment using
in vitro as well as in vivo models. Our results demonstrate that
ectopic expression of miR-34a strongly suppresses multiple
tumorigenic functions (e.g. proliferation, and colony formation)
of head and neck cancer cells. In addition, ectopic expression of
miR-34a significantly inhibited cell migration even after taking
into account the effect of miR-34a on cell proliferation at the same
time point (60% cell migration inhibition as compared to 20% cell
proliferation inhibition at 24 hrs). These tumor suppressive effects
of miR-34a are mediated by changes in a number of target
mRNAs including MYCN, CDK4, cyclin D1, SIRT1 and Bcl-2
[18,51,52,53]. In this study, we looked at changes in protein
expression of some of the known targets of mir-34a (e.g. SIRT1,
CDK4, E2F3) and found them to be altered upon ectopic miR-
34a expression (Figure S1). We decided to conduct an in-depth
Figure 6. miR-34a inhibits tumor angiogenesis by downregulating VEGF secretion from tumor cells. A-B: Paraffin embedded tumor
samples were stained with anti-CD31 antibody and microvessel density was calculated by counting 5 random high power fields (200x). A:
Representative photographs of UM-SCC-74A tumors expressing scrambled control microRNAs (SC) or miR-34a. B: Microvessel density in tumor
samples from scrambled control microRNAs (SC) or miR-34a groups. *, represent a significant inhibition (p,0.05) of tumor angiogenesis in miR-34a
group as compared to SC. C: VEGF levels (pg/ml per 10
6 tumor cells) in culture supernatants from UM-SCC-74A cells transfected with miR-34a or
scrambled control microRNA (SC). D: Representative photographs of UM-SCC-74B tumors expressing scrambled control microRNAs (SC) or miR-34a. E:
Microvessel density in tumor samples from scrambled control microRNAs (SC) or miR-34a groups. F: VEGF levels (pg/ml per 10
6 tumor cells) in culture
supernatants from UM-SCC-74B cells transfected with miR-34a or scrambled control microRNA (SC).
doi:10.1371/journal.pone.0037601.g006
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study we show that miR-34a mediates its tumor suppressor effects
predominantly through E2F3a isoform, as overexpression of miR
resistant E2F3a significantly rescued the effects of miR-34a on cell
proliferation and colony formation. Recently, Chen et al,
demonstrated that out of two different E2F3 isoforms, E2F3a
showed significantly higher oncogenic potential as compared to
E2F3b [54]. Similarly, Reimer et al, have shown that although
both E2F3 isoforms were overexpressed in tumor samples, but
only E2F3a expression directly correlated with tumor stage and
residual disease in ovarian cancer patients [55]. In addition, the
same group has also shown that there was a strong correlation
between E2F3a expression and activated EGFR in ovarian cancer
specimens and that E2F3a was a key player in EGFR driven cell
proliferation [56]. The EGFR pathway is abnormally activated in
HNSCC and overexpression of EGFR has been associated with
poor response to chemotherapy and poor survival in head and
neck cancer patients [57]. Partial rescue of miR-34a function by
E2F3b in our studies could be due to some functional overlap
often observed in E2F3a and E2F3b [28,30]. Another important
observation we made in this study is that ectopic expression of
miR-34a in head and neck cancer cells also significantly down-
regulated survivin expression. Recently, miR-34a was shown to
modulate survivin promoter activity [34]. However, it is not
known if miR-34a-mediated regulation of survivin promoter
activity is due to its direct effect or mediated via another protein.
Our rescue experiments with miR resistant E2F3a suggest that
miR-34a may be inhibiting survivin expression via E2F3a [35].
We also observed an inverse correlation between miR-34a and
survivin expression (low miR-34a and high survivin) in most of the
Figure 7. miR-34a inhibits endothelial cell proliferation, migration and tube formation. A: miR-34a expression in endothelial cells
expressing Bcl-2 (EC-Bcl-2) or vector alone (EC-VC) was analyzed by real time RT-PCR. B-C: Endothelial cells (EC) transfected with 50 nM of miR-34a or
scrambled control RNA (SC) were used for different assays after 48 hrs of transfection. Endothelial cell proliferation (B) and cell migration (C) was
measured using Xcelligence system. D: Endothelial cell tube formation assay was performed on Matrigel coated lab-tech chamber slides. At the end
of assay, each chamber was photographed under microscope, and the area occupied by endothelial cell tubes was calculated using NIS-Elements-BS
software (Nikon) and expressed as an angiogenic score (E). Whole cell lysates were Western blotted (72 hrs post transfection) and probed with
specific antibodies against E2F3a/b, SIRT1, survivin and CDK4 proteins. Equal protein loading in Western blotting was verified by stripping the blots
and reprobing with tubulin antibody.
doi:10.1371/journal.pone.0037601.g007
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oncogene and its expression is directly associated with enhanced
proliferation, resistance to chemotherapy [58,59], reduced apo-
ptosis [60], enhanced angiogenesis [61], poor outcome [58,62]
and increased rate of tumor recurrence [63]. These results provide
a novel mechanistic role for the miR-34a-E2F3a-survivin axis in
mediating miR-34a tumor suppressor function.
The strong tumor suppressor effect of miR-34a on HNSCC cell
lines observed during in vitro assays was further supported by its
effects on in vivo xenograft tumor growth. In addition, miR-34a
also significantly inhibited tumor angiogenesis by downregulating
a key angiogenic factor VEGF. It has been shown that VEGF
levels can be regulated by a number of miR-34a target proteins
including E2F3, Myc and c-met [36,37,38]. Furthermore, our
results demonstrate that miR-34a can also regulate tumor
angiogenesis by directly inhibiting angiogenic functions of
endothelial cells by downregulating a number of key proteins
including E2F3, SIRT1, survivin and CDK4. Taken together, our
results demonstrate an important tumor suppressor and anti-
angiogenic function for miR-34a in head and neck cancers.
Materials and Methods
Ethics Statement
This study was approved by the institutional review board at the
Ohio State University and complied with all provisions of the
Declaration of Helsinki. All animal work has been conducted
according to the Ohio State University IACUC Animal ethic
committee and was approved by this committee (Animal Welfare
Assurance Number A3261-01).
Patient Samples, Cell Lines and Reagents
Tumor and adjacent normal tissue samples were collected from
head and neck cancer patients undergoing surgical resection at the
James Comprehensive Cancer Center at The Ohio State
University. Use of these tissues was approved by the Ohio State
University institutional review board. A board certified pathologist
diagnosed all tumor tissue as HNSCC. Normal samples were
collected from areas adjacent to the tumor tissue but outside the
tumor margins. RNA was isolated from fresh frozen tissues
samples using TRIzol reagent (Invitrogen). The isolated RNA was
dissolved in RNase-free water and stored at 270uC. Out of the 15
tumor samples, 6 were from oral cavity, 5 from oropharynx and 4
from larynx. Head and neck squamous cell carcinoma (HNSCC)
cell lines UM-SCC-74A, UM-SCC-74B, UM-SCC-47, UM-SCC-
49, UM-SCC-38 were obtained from Dr. Thomas E. Carey
(University of Michigan). UD-SCC-2 was obtained from Dr.
Henning Bier (Heinrich-Heine University, Germany). CAL 27,
FaDu and SCC-25 were purchased from ATCC. The identity of
all the tumor cell lines was confirmed by STR genotyping
(Identifiler Kit, Applied Biosystems, Carlsband, CA) and cell line
characteristics are presented in Table S1. Normal human oral
keratinocytes (HOK) were purchased from ScienCell (Carlsbad,
CA). Human epidermal keratinocytes, adult (HEKa) and human
epidermal keratinocytes, neonatal (HEKn) were purchased from
Invitrogen (Carlsbad, CA). All HNSCC cell lines, except SCC-25
were cultured in DMEM supplemented with 10% fetal bovine
serum containing 1% penicillin/streptomycin (Invitrogen, Carls-
bad, CA) and 1% Non-essential amino acids. SCC-25 was
cultured in DMEM/F12 supplemented with 10% FBS, 1%
penicillin/streptomycin, 400 ng/ml hydrocortisone. HOK, HEKa
and HEKn were grown in keratinocyte growth medium (Invitro-
gen, Carlsbad, CA). Primary human dermal microvascular
endothelial cells (ECs) were purchased from Lonza (Walkersville,
MD). ECs were maintained in Endothelial Cell Basal Medium-2
(EBM-2) containing 5% FBS and growth supplements. Primary
antibody against E2F3a (clone 3E2F04) was purchased from
Thermo Scientific (Fremont, CA), E2F3a/b (C-18) and CDK4 (C-
260) from Santa Cruz (Santa Cruz, CA), CD31 (clone MEC 13.3)
from Diannova (Franklin Lakes, NJ) and survivin, SIRT1 and
tubulin were purchased from Cell Signaling (Danvers, MA).
Quantitative Reverse-transcription PCR (qRT-PCR)
RNA was extracted from the HNSCC cell lines and normal
keratinocytes (HOK, HEKa and HEKn) using the MirVANA kit
(Ambion). TaqMan microRNA assay specific for miR-34a (Assay
ID 000426) was used to detect and quantify mature miR-34a. For
Survivin qRT-PCR, RNA was transcribed into cDNA and
amplified with TaqMan primer/probe (Hs03043576_m1). The
assays were performed in accordance with manufacturer’s
instructions (Applied Biosystems, Carlsband, CA). miRNA and
mRNA expression was normalized to RNU48 and OAZ1,
respectively using the 2
-DDCt method [64].
Ectopic Expression of miR-34a in HNSCC Cells and
Endothelial Cells
Precursor human miR-34a or scrambled control miRNA
(Applied Biosystems) transfection in HNSCC tumor cells and
EC was performed using Lipofectamine 2000 (Invitrogen) as per
manufacturer’s instructions. In brief, HNSCC cells or endothelial
cells were cultured in 6-well plates till they reached 60%
confluence. Cells were washed and further cultured in the
respective growth media minus antibiotics. In separate tubes,
miR-34a (50 nM) and lipofectamine 2000 were diluted in OPTI-
MEM medium and incubated for 5 minutes. After incubation,
miR-34a and lipofectamine were mixed together and further
incubated for 30 minutes. At the end of incubation, miR-34a and
lipofectamine solution was carefully added to 6-well plates
containing cells. After 24 hours, cells were washed and cultured
in complete growth media containing antibiotics. To check
transfection efficiency, FITC-labeled scrambled miRs were used
and we consistently observed .80% transfection efficiency.
Seventy two hours post transfection, cells were used for all the
subsequent experiments.
Transduction of Tumor Cells with E2F3a and E2F3b
Retroviral particles were used to overexpress miR resistant
E2F3a and E2F3b [29] (a kind gift from Dr. Brian D. Dynlacht,
New York University) in head and neck cancer cell lines as
described previously [65]. In brief, the E2F3a and E2F3b
constructs or the vector alone was introduced into PT67
amphotropic packing cells with Lipofectamine 2000. Viral super-
natants were collected after 24 h, centrifuged, filtered, and stored
at 280
oC. Head and neck tumor cells (UM-SCC-74A and UM-
SCC-74B) were transduced with viral supernatants supplemented
with 4 mg/ml polybrene 3 times every 4 hrs. The last infection was
left overnight and the next morning cells were washed and
cultured in fresh medium. Stable clones overexpressing E2F3a and
E2F3b were selected by treating with puromycin (2 mg/ml) for 3
days.
Cell Proliferation
Tumor and endothelial cell proliferation were examined by
MTT assay [66] (Roche Diagnostics, Indianapolis, IN) and
Xcelligence system [67] using the RTCA DP instrument (Roche,
Mannheim, Germany). For MTT assay, tumor or endothelial cells
were plated in flat-bottomed 96-well microtitre plates at a density
miR-34a Inhibits HNSCC Tumor Growth
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e37601of 2610
3 and 5610
3 cells/well respectively. At the completion of
incubation, cell proliferation was assessed by adding 10 ml of MTT
labeling reagent into each well and incubating at 37uC for 4–6 hrs
(4 hrs for tumor cells and 6 hrs for HDMEC). Reaction was
stopped by adding solubilization solution and incubating the plates
at 37uC overnight. The plates were read on a microplate reader
(Sectramax 190, Molecular Devices Corp., Sunnyvale, CA) at
a wavelength of 590 nm. The percentage cell proliferation for
each group was calculated by adjusting the control group to 100%.
For Xcelligence system proliferation assay, 100 ml of media
(DMEM for tumor cells and EGM for EC) containing 2% FBS
was added to the wells. After 1 hr of equilibration with media,
100 ml of cell suspension (3,000 tumor cells or 5,000 endothelial
cells) was added to each well. Cell proliferation was monitored and
expressed as percentage cell proliferation.
Motility Assay
Tumor and endothelial cell motility were examined by scratch
assay [66] and Xcelligence system [67]. For scratch motility assay,
a fine groove was made using a sterile pipette tip in about 90%
confluent cells. The migration of cells was monitored microscop-
ically using Nikon Eclipse Ti microscope with DS-Fi1 camera. For
Xcelligence system migration assay, 160 ml of media (DMEM for
tumor cells and EGM for EC) containing 10% FBS was added to
the lower chambers. Upper chamber (sensor surface facing down)
was then carefully assembled on top of lower chamber and 50 ml
of serum free media was added to the wells. After 1 hr of
equilibration with media, 100 ml of cell suspension (50,000 cells/
well in serum free media) was added to each well. Cell migration to
lower chamber was monitored and expressed as cell migration
index at 24 hrs.
Tumor Cell Colony Formation Assay
Tumor cells (5x10
3) were plated in 60 cm petri dishes and
cultured at 37uC. After 14 days of culture, colonies were stained
with crystal violet (0.005%) for 20 minutes and photographed.
Alpha Innotech (San Leandro, CA) imaging software was used to
quantify tumor cell colony numbers.
ELISA
Tumor cells were cultured in 6-well plates till they are 80%
confluent. Cells were washed and fresh media was added. After 24
hours, culture supernatants were collected and cell number in each
well was counted. VEGF levels in culture supernatants were
measured using Quantikine human ELISA kits (R&D Systems,
Minneapolis, MN) as per manufacturer’s instructions and
normalized to 1x10
6 cells.
Western Blot Analysis
Whole cell lysates were separated by 4–12% NuPAGE Bis-Tris
gels (Invitrogen, Carlsbad, CA) and transferred onto PVDF
membranes. Nonspecific binding was blocked by incubating the
blots with 3% BSA in Tris buffered saline containing 0.1%
Tween-20 (TBST) for 1 hr at room temperature (RT). The blots
were then incubated with primary antibody in TBST +3% BSA at
4uC overnight. After washing with TBST, the blots were
incubated with horseradish peroxidase-conjugated sheep anti-
mouse IgG (1:5,000) or with donkey anti-rabbit IgG (1:5,000) for
1 hr at RT. An ECL-plus detection system (GE Healthcare,
Piscataway, NJ) was used to detect specific protein bands. Protein
loading in all the experiments was normalized by stripping the
blots and then re-probing with anti-tubulin antibody. Alpha
Innotech (San Leandro, CA) imaging software was used to
quantify Western blot bands.
Matrigel in vitro Endothelial Tube Formation Assay
Endothelial cell tube formation was performed on Matrigel
coated chamber slides as described previously [68]. Each assay was
photographed (Nikon Eclipse Ti microscope with DS-Fi1 camera)
at 40x magnification and total area occupied by endothelial cell
derived tubes in each chamber was calculated using software (NIS-
Elements-Basic Research, Nikon, Melville, NY) and expressed as
an angiogenic score.
Xenograft Tumor Model
Tumor cells (1 x10
6) were mixed with 100 ml of Matrigel and
injected subcutaneously in the flanks of SCID mice (n=5) as
described previously [40]. Tumor volume measurements began on
day 3 and continued twice a week until the end of the study. The
length and width of the tumors were measured using a digital
caliper and tumor volumes were calculated using the formula,
volume (mm
3)=L 6W
2/2 (length L, mm; width W, mm). After 18
days, tumors samples were carefully removed. A piece of each of
the primary tumor was used to extract RNA to confirm the
presence of miR-34a by real-time PCR. Rest of the tumors were
fixed with 4% paraformaldehyde and then processed to form
paraffin embedded tissue blocks for immunohistochemistry.
Tumor sections were stained for angiogenesis (CD31) as described
previously [68]. Microvessel density was calculated by counting
5 random high power fields (200x).
Statistical Analysis
Data from all the experiments are expressed as mean 6 SEM
from a minimum of 3 independent experiments. The miR-34a
expression in patient samples and head and neck cancer cell lines
(Figure 1) was analyzed by Mann-Whitney test. To examine the
inverse relationship between miR-34a and survivin expression in
patient samples (Figure 4F), miR-34a levels for each tumor sample
was plotted against the inverse of survivin levels and Pearson
correlation coefficient was calculated. The rest of the data was
statistically analyzed by two-way analysis of variance or Student’s
t test (wherever applicable) and a p value of ,0.05 was considered
significant.
Supporting Information
Figure S1 miR-34a significantly downregulates SIRT1,
CDK4, E2F3a/b and survivin protein expression. UM-
SCC-74A cells were transfected with miR-34a or SC. Seventy two
hrs after transfection whole cell lysate was prepared and Western
blotted using antibody specific for SIRT1 (top panel) or CDK4
(second panel) or E2F3a/b (third panel) or survivin (fourth panel).
Equal protein loading in Western blotting was verified by stripping
the blots and reprobing with tubulin antibody.
(TIF)
Figure S2 miR-34a significantly inhibits tumor cell
proliferation. UM-SCC-74A cells were transfected with miR-
34a or SC. Seventy two hrs after transfection, cells were plated in
96 well plates and cell proliferation was examined at different time
points using MTT assay.
(TIF)
Table S1 Head and neck cancer cell line characteristics.
(TIF)
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